Form 4: Apyx Medical CFO Receives Stock Option Grant

Apyx Medical Corporation CFO Matthew C. Hill was granted 132,066 stock options as part of an equity incentive plan.

Summary

• Matthew C. Hill, Chief Financial Officer of Apyx Medical Corporation, was granted 132,066 stock options on June 11, 2026.
• The options have an exercise price of $4.65 per share.
• The grant vests ratably over a 36-month period, becoming fully exercisable on June 11, 2029.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of executive interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future shareholder dilution upon the exercise of these options.

Risks

• Market price volatility may impact the future value of the granted options.
• The value of the options is contingent upon the company's stock performance exceeding the $4.65 strike price.

Future Outlook

The options vest over a three-year period, indicating a long-term retention and performance incentive for the CFO.

Industry Context

StockSavvy.ai notes that equity grants to C-suite executives are standard corporate governance practices intended to align management incentives with long-term company performance in the medical device sector.

Comparison to Industry Standards

• The use of 36-month ratable vesting is consistent with standard executive compensation packages in the small-cap medical technology industry.

Stakeholder Impact

• Shareholders may experience minor dilution if options are exercised in the future.

Next Steps

• Vesting of options over the next 36 months.
• Potential exercise of options by the reporting person after vesting.

Key Dates

Keywords

Apyx Medical, APYX, Form 4, Insider Trading, Stock Options, CFO, Equity Compensation